First Trust Advisors’s GeneDx Holdings WGS Stock Holding History

First Trust Advisors’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-74,602	Closed	-$4.79M	–	2764
2026 Q1	$4.79M	Buy	74,602 +12,552	+20%	+$1.14M	﹤0.01%	1467
2025 Q4	$8.07M	Sell	62,050 -2,051	-3%	-$282K	0.01%	1187
2025 Q3	$6.91M	Buy	64,101 +1,722	+3%	+$188K	0.01%	1241
2025 Q2	$5.76M	Buy	+62,379	New	+$4.9M	﹤0.01%	1291

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

First Trust Advisors's WGS Position: Q2 2026 in Review

First Trust Advisors sold out of GeneDx Holdings (WGS) in Q2 2026, closing a stake of 74,602 shares — an estimated $4.79M sold.

First Trust Advisors first reported a position in WGS in Q2 2025 and held it in 4 quarters. The position peaked at $8.07M in Q4 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

First Trust Advisors reported no remaining GeneDx Holdings position as of Q2 2026 after selling out during the quarter.
First Trust Advisors sold 74,602 GeneDx Holdings shares in Q2 2026, an estimated $4.79M.
First Trust Advisors first reported a position in GeneDx Holdings in Q2 2025 and held it in 4 quarters.
First Trust Advisors's GeneDx Holdings position peaked at $8.07M in Q4 2025.
223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.